Jasper Therapeutics Reports IND Clearance For Phase 1b/2a Study Of Subcutaneous Briquilimab In Chronic Spontaneous Urticaria
Portfolio Pulse from Benzinga Newsdesk
Jasper Therapeutics has received IND clearance for a Phase 1b/2a study of subcutaneous Briquilimab in Chronic Spontaneous Urticaria. The study will enroll around 40 patients across 6 cohorts, focusing on safety, tolerability, efficacy measures, and pharmacokinetics of Briquilimab.
October 09, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jasper Therapeutics' IND clearance for Phase 1b/2a study of Briquilimab could potentially boost investor confidence in the company's research and development capabilities.
The IND clearance is a regulatory approval that allows Jasper Therapeutics to proceed with its Phase 1b/2a study. This indicates that the company's research and development efforts are progressing, which could potentially boost investor confidence and positively impact the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100